OTCMKTS:VDRM ViaDerma (VDRM) Stock Price, News & Analysis → Emergency: Biden's $20 Trillion Mistake Could Cost YOU! (From GoldenCrest Metals) (Ad) Free VDRM Stock Alerts 0.0094 0.00 (-5.05%) (As of 06:35 PM ET) Add Compare Share Share Today's Range0.01▼0.0150-Day Range0.01▼0.0152-Week Range0.01▼0.02Volume107,100 shsAverage Volume1.62 million shsMarket CapitalizationN/AP/E Ratio0.00Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get ViaDerma alerts: Email Address Ad GoldenCrest MetalsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.Learn More Now About ViaDerma Stock (OTCMKTS:VDRM)ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas. The company's lead product is Vitastem, a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. It is also developing products in various fields of use, including topical antibiotics, toenail antifungal drugs, diabetic amputations, global acne, psoriasis, and eczema, as well as burns, anti-aging/wrinkle remover creams, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company was formerly known as Décor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California.Read More VDRM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VDRM Stock News HeadlinesMarch 3, 2024 | morningstar.comViaDerma Inc VDRMOctober 24, 2023 | finance.yahoo.comViaDerma Update on Stability Testing, Global Sales Distribution, National Licensing, Nupelo & MoreApril 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.July 6, 2023 | finance.yahoo.comViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & MoreApril 18, 2023 | finance.yahoo.comViaDerma, Inc. (VDRM) Stock Historical Prices & Data - Yahoo FinanceMarch 16, 2023 | finance.yahoo.comViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth ProductMarch 8, 2023 | finance.yahoo.comViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth ProductMarch 2, 2023 | finance.yahoo.comViaDerma Provides an Update on Current & Future Business ActivitiesApril 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.January 12, 2023 | benzinga.comViaDerma Retains Digital Marketing Leader INTENT SCIENCES to Accelerate Business Growth OnlineSeptember 15, 2022 | finance.yahoo.comViaDerma Successfully Completes Quality Control Testing of its New Vitastem ProductsJune 22, 2022 | finance.yahoo.comViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem ProductsApril 1, 2022 | nz.finance.yahoo.comAvoteo emerges as the first crowdfunding platform without spending moneyApril 1, 2022 | yahoo.comVictoria and David Beckham's UK home 'burgled' while daughter Harper was asleep upstairsApril 1, 2022 | yahoo.comOur existence isn't new, but now transgender people are visible like never beforeMarch 31, 2022 | finance.yahoo.comViaDerma's 2021 Annual Report Shows Strong Revenue Growth Over the Previous YearOctober 4, 2021 | finance.yahoo.comViaDerma, Inc. Set to Launch Two New and Improved Versions of its Flagship Product, Vitastem and Vitastem UltraAugust 24, 2021 | finance.yahoo.comViaDerma, Inc. Files Amended Financial StatementsAugust 21, 2021 | barrons.comViaDerma Inc.See More Headlines Receive VDRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ViaDerma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:VDRM CUSIPN/A CIKN/A Webviadermalicensing.com Phone(310) 734-6111FaxN/AEmployees75Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.00 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Qing Hua Lin (Age 43)Chief Financial Officer and Director Comp: $4.46kMr. Baotang Zhao (Age 46)Chief Sales Officer Comp: $28.77kMr. Zhang Xie (Age 45)Corporate Secretary and Director Comp: $9.18kDr. Christopher A OtikoFounder, Chief Executive Officer and PresidentDr. Andrew Berman M.D.MPH, Medical Director and Member of Advisory BoardKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors VDRM Stock Analysis - Frequently Asked Questions How have VDRM shares performed in 2024? ViaDerma's stock was trading at 0.01 at the start of the year. Since then, VDRM stock has decreased by 11.3% and is now trading at 0.01. View the best growth stocks for 2024 here. Are investors shorting ViaDerma? ViaDerma saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 4,800 shares, a decline of 92.7% from the February 29th total of 65,800 shares. Based on an average daily volume of 2,553,200 shares, the short-interest ratio is presently 0.0 days. View ViaDerma's Short Interest. How do I buy shares of ViaDerma? Shares of VDRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:VDRM) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe Greatest Bull Market in Crypto History…Weiss RatingsNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ViaDerma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
